99 results
Page 3 of 5
8-K
sf9 n7s08etp
25 May 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
EX-99.1
x8f hxfh6rkph33js
16 Feb 22
Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol
7:39am
424B5
pznruxqp6x0be4qcexbl
13 Dec 21
Prospectus supplement for primary offering
9:19am
424B5
8y535hdt5f78
10 Dec 21
Prospectus supplement for primary offering
5:25pm
424B5
8zk6nlzztg0 fk
10 Nov 21
Prospectus supplement for primary offering
5:25pm
424B5
64mgoz
9 Nov 21
Prospectus supplement for primary offering
5:14pm
8-K
EX-99.1
rpvbywmbz663r 3684
14 Jun 21
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
9:00am
8-K
EX-99.1
vxrej 20kvqjbmnn1xf
17 Dec 20
Avenue Therapeutics Provides Regulatory Update for IV Tramadol
9:02am
8-K
EX-99.1
9qsq57
13 Oct 20
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
6:10am
8-K
EX-99.1
5lfbmgydtu2rw
14 Aug 20
Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
8:30am
DEFA14A
j21dpj7n5976gi
29 May 20
Additional proxy soliciting materials
9:30am